Circio Holding ASA (0RIS)

Profile

https://www.circio.com

Circio Holding ASA is a clinical-stage biotechnology company headquartered in Lysaker, Norway, specializing in the development of novel circular RNA (circRNA) therapeutics and immuno-oncology immunotherapies for treatment-resistant cancers and difficult-to-treat diseases. Formerly known as Targovax ASA until its rebranding in May 2023, the company pioneers proprietary platforms like circVec, a modular genetic cassette enabling efficient biogenesis of multifunctional circRNAs in human cells, and circAde, an engineered adenovirus delivery system targeting cancer cells. These technologies promise up to 15-fold enhanced protein expression and 70-fold greater durability compared to conventional mRNA systems, positioning circRNA as a potential gold standard for gene therapy, cell therapy, and nucleic acid medicines. Circio's pipeline includes the pan-RAS cancer vaccine TG01, in Phase 1/2 trials for multiple myeloma, pancreatic, lung cancer, and other indications through collaborations with institutions like Oslo University Hospital and Agenus, alongside oncolytic virus ONCOS-102. With approximately 9 employees and R&D centered at Sweden's Karolinska Institute, Circio plays a niche role in advancing next-generation oncology and genetic therapies within the biotechnology sector.